Understanding how estrogen affects cell signaling through specific RNA molecules.
Official title: Analysis of divergent transcripts in estrogen-dependent signaling.
Funded at Texas Tech University Health Sciences Center at El Paso · NIH-10923793 · Data updated 2026-11-12
This study is looking at how the hormone estrogen works in breast cancer cells, especially focusing on a special type of RNA that might help control how these cells respond to estrogen, which could lead to better understanding and treatment of related diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Sciences Center at El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project start | September 10, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $160,000 |
| NIH project number | 5R16GM149497-02 |
| Project ID | NIH-10923793 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with estrogen receptor-positive breast cancer or those affected by conditions related to estrogen signaling.
✕Less likely to help
Patients with estrogen receptor-negative breast cancer or those not affected by estrogen-related conditions may not benefit from this research.
What this research studies
This research investigates how the hormone estrogen interacts with its receptor in breast cancer cells, focusing on a specific type of RNA called divergent transcripts. These transcripts are believed to play a crucial role in regulating the cellular responses triggered by estrogen. By using advanced cellular and genomic techniques, the study aims to uncover the molecular mechanisms that govern how these transcripts influence estrogen-driven gene expression and cellular activities. This understanding could provide insights into diseases linked to abnormal estrogen signaling.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for breast cancer and other conditions influenced by estrogen signaling.
How similar studies have gone: Previous research has shown promising results in understanding estrogen signaling and its implications in breast cancer, suggesting that this approach has potential for significant findings.
Where this research is happening
-
Texas Tech University Health Sciences Center at El Paso
El Paso, United States Active
Researchers
- Principal investigator: Gadad, Shrikanth — Texas Tech University Health Sciences Center at El Paso
- Study coordinator: Gadad, Shrikanth
Related research
Other NIH-funded projects on the same topics.
-
Pediatric and Young Adult Gastroparesis Registry and Disease Course
This project follows children, teens, and young adults with symptoms of gastroparesis to learn how their symptoms change over time and what factors are tied to different disease patterns.
-
Prucalopride for gastroparesis in adults: a multi-site trial
A multicenter study tests a medicine called prucalopride to help adults with gastroparesis feel better and have fewer stomach symptoms.
-
How the mitochondrial protein PSAP affects nerve cell survival in ALS
This research looks at whether lowering a mitochondrial protein called PSAP can protect motor neurons and help people with ALS.
-
Pediatric Gastroparesis Registry 2: tracking symptoms and gastric emptying in kids and young adults
This registry follows children, teens, and young adults (ages 8–25) with symptoms like nausea, vomiting, bloating, early fullness, or abdominal pain to document symptom patterns, gastric emptying, and quality of life over time.
-
Mitochondrial protein PSAP’s role in ALS: protecting motor neurons by controlling cell death and cleaning up damaged parts
This grant studies how a mitochondrial protein called PSAP may protect nerve cells in ALS by balancing cell death and cellular cleanup, with experiments in animal models to see if boosting PSAP helps motor function and survival.
-
How KSHV hides from the immune system via complement and Fc-receptor proteins
Researchers are looking at how the virus that causes Kaposi sarcoma (KSHV) uses complement and Fc-receptor proteins to hide from the immune system, to help people with KSHV-related cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.